FIELD: medicine, pharmaceutics.
SUBSTANCE: group of invention relates to medicine, namely - to oncology and can be used for treatment of a neoplasm associated with excessive expression or amplification of .epidermal growth factor receptor 2 (HER2). According to the invention, the method includes administration of an effective quantity of the active components combination containing herceptin and CCI-779 (temsirolimus). Additionally, the group of inventions deals with versions of the herceptin and CCI-779 combination application for production of an anti-tumour medication.
EFFECT: use of the inventions allows higher effectiveness of treatment of cancer associated with excessive expression or amplification of HER2.
30 cl, 3 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| ANTICANCER ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CARCINOMA | 2008 |
|
RU2501559C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2013 |
|
RU2670974C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
| CD37-IMMUNOTHERAPEUTIC COMBINATION THERAPY AND USING IT | 2009 |
|
RU2526156C2 |
| ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
